移植前肝癌降期：免疫治疗与局部区域治疗的作用。
Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
机构信息
Department of Surgery, Division of Abdominal Organ Transplantation, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8109, St Louis, MO 63110, USA.
Department of Surgery, Division of Abdominal Organ Transplantation, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8109, St Louis, MO 63110, USA.
出版信息
Surg Oncol Clin N Am. 2024 Jan;33(1):143-158. doi: 10.1016/j.soc.2023.07.001. Epub 2023 Sep 16.
Hepatocellular carcinoma (HCC) continues to be a leading cause of cancer-related death in the United States. With advances in locoregional therapy for unresectable HCC during the last 2 decades and the recent expansion of transplant criteria for HCC, as well as ongoing organ shortages, patients are spending more time on the waitlist, which has resulted in an increased usage of locoregional therapies. The plethora of molecularly targeted therapies and immune checkpoint inhibitors under investigation represent the new horizon of treatment of HCC not only in advanced stages but also potentially at every stage of diagnosis and management.
肝细胞癌 (HCC) 仍然是美国癌症相关死亡的主要原因。在过去 20 年中，局部区域治疗不可切除 HCC 的进展以及 HCC 移植标准的最近扩大，以及持续的器官短缺，导致患者在等待名单上花费的时间更多，这导致了局部区域治疗的使用增加。大量正在研究的分子靶向治疗和免疫检查点抑制剂不仅代表了 HCC 晚期治疗的新领域，而且还可能代表了诊断和管理的每个阶段的治疗新领域。
Zotero 插件